Skip to main content
. 2021 Mar 19;11:656184. doi: 10.3389/fonc.2021.656184

Figure 2.

Figure 2

CVBD induces apoptosis in GBM cells. (A, B) T98G and U251 cells were exposed to various concentrations of CVBD (80, 120, 160 μM) for 24 h, and 0 μM CVBD was used as the control group. Apoptosis was detected by AnnexinV-FITC/PI staining and flow cytometry. (C, D) T98G and U251 cells were treated as indicated in (A, B). The total cellular extracts of T98G and U251 cells were determined by Western blotting using antibodies against total PARP, cleaved PARP (C-PARP), and cleaved-Caspase3 (C-Caspase3) (mean ± SD of three independent experiments, *P < 0.05, **P < 0.01, ***P < 0.001 compared with the control group). GAPDH was used as a loading control. (E, F) T98G and U251 cells were pre-treated with Z-VAD-FMK (20 μM, 2 h) and post-treated with CVBD (120 μM) for 24 h. Apoptosis was detected by AnnexinV-FITC/PI staining and flow cytometry. (G, H) T98G and U251 cells were treated as indicated in (E). The expression level of PARP, C-PARP, and C-Caspase3 were determined by Western blotting analysis. GAPDH was used as a loading control (mean ± SD of three independent experiments, ***P < 0.001 compared with CVBD treatment alone).